Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis.

Geng J, Ito Y, Shi L, Amin P, Chu J, Ouchida AT, Mookhtiar AK, Zhao H, Xu D, Shan B, Najafov A, Gao G, Akira S, Yuan J. · 2017

Read Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis. by Geng J, Ito Y, Shi L, Amin P, Chu J, Ouchida AT, Mookhtiar AK, Zhao H, Xu D, Shan B, Najafov A, Gao G, Akira S, Yuan J. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5572456.txt.

Introduction

Geng and co-authors report a cell-death study in Nature Communications. One signal, TNF, can push a cell toward three different deaths. The protein RIPK1 sits at the switch. How the cell picks a path was unclear.

A second protein, TAK1, tags RIPK1 with phosphate groups. The tag pattern decides the outcome. A brief tag at one site favors ordinary apoptosis when survival signals are off. No tag lets RIPK1 bind FADD and drive a kinase-led apoptosis. A lasting tag at many sites pairs RIPK1 with RIPK3. That pairing triggers necroptosis, a bursting form of death. The team tracked the key site, Ser321, as a marker. Readers get a timing code for life-and-death decisions.

Catalog record

CREATORGeng J, Ito Y, Shi L, Amin P, Chu J, Ouchida AT, Mookhtiar AK, Zhao H, Xu D, Shan B, Najafov A, Gao G, Akira S, Yuan J.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5572456

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis By Jiefei Geng, Yasushi Ito, Linyu Shi, Palak Amin, Jiachen Chu, Amanda Tomie Ouchida, Adnan Kasim Mookhtiar, Heng Zhao, Daichao Xu, Bing Shan, Ayaz Najafov, Guangping Gao Published in: Nature Communications DOI: 10.1038/s41467-017-00406-w ABSTRACT Stimulation of TNFR1 by TNFα can promote three distinct alternative mechanisms of cell death: necroptosis, RIPK1-independent and -dependent apoptosis. How cells decide which way to die is unclear. Here, we report that TNFα-induced phosphorylation of RIPK1 in the intermediate domain by TAK1 plays a key role in regulating this critical decision. Using phospho-Ser321 as a marker, we show that the transient phosphorylation of RIPK1 intermediate domain induced by TNFα leads to RIPK1-independent apoptosis when NF-κB activation is inhibited by cycloheximide. On the other hand, blocking Ser321 phosphorylation promotes RIPK1 activation and its interaction with FADD to mediate RIPK1-dependent apoptosis (RDA). Finally, sustained phosphorylation of RIPK1 intermediate domain at multiple sites by TAK1 promotes its interaction with RIPK3 and necroptosis. Thus, absent, transient and sustained levels of TAK1-mediated RIPK1 phosphorylation may represent distinct states in TNF-RSC to dictate the activation of three alternative cell death mechanisms, RDA, RIPK1-independent apoptosis and necroptosis. INTRODUCTION RIPK1, a member of the receptor-interacting protein (RIP) serine-threonine kinase family, has emerged as a key upstream regulator that controls multiple downstream signaling pathways of TNFR11, 2. Within minutes after cells stimulated by TNFα, RIPK1 is recruited into the TNFR1 signaling complex (TNF-RSC, also called complex I) together with signaling molecules such as TRADD, TRAF2 and cIAP1/2 to decide if a cell and ultimately, an organism, may live or die through apoptosis or necroptosis. Apoptosis may be mediated by binding of RIPK1, independent of its kinase activity, with FADD, an adaptor protein for caspase-8, which in turn promotes the activation of caspase-8 and executes apoptosis by triggering mitochondrial damage and the cleavage of downstream caspases such as caspase-3. Under apoptotic deficient conditions, RIPK1 may be activated to promote necroptosis by interacting with RIPK3 which in turn promotes the phosphorylation of MLKL to mediate the execution of necroptosis. Ubiquitination of RIPK1 by cIAP1/2 in TNF-RSC is involved in mediating the activation of NF-κB by recruiting TAB1/2 to promote the activation of the TAK1 (transforming growth factor-β-activated kinase 1, also called MAP3K7)3. Activated TAK1 mediates the phosphorylation of IKKβ to promote the formation of the IKK complex consisting of IKKα/β/γ(NEMO)4. Although the best characterized function of TAK1 and the IKK complex including NEMO is to mediate the activation of NF-κB pathway, recent studies have unveiled that deficiencies in TAK1, NEMO, IKKα/β or the loss of cIAP1/2 can sensitize cells to RIPK1-dependent apoptosis (RDA) independently of their roles in NF-κB activation5, 6. On the other hand, in cells deficient for A20, an important ubiquitin-editing enzyme for RIPK1, or TAB2, which regulates the activation of TAK1, RIPK1 may be activated to interact with RIPK3 to mediate necroptosis7, 8. It is not clear, however, how activated RIPK1 might be directed to mediate two alternative modes of cell death, RDA or necroptosis, that both occur in a RIPK1 kinase-dependent manner. RIPK1 contains an N-terminal kinase domain, an intermediate domain and a C-terminal death domain1. The kinase activity of RIPK1 may be activated upon stimulation of TNFR1 by TNFα under selective conditions, which leads to multiple deleterious consequences including cell death and inflammation. Inhibition of RIPK1 kinase activity using improved necrostatin-1 (R-7-Cl-O-Nec-1, Nec-1s), a highly specific small molecule inhibitor of RIPK1, and the use of RIPK1 kinase-dead mutant mice, have shown efficacy in a wide range of animal models of human diseases9–11. Small molecule inhibitors of RIPK1 are under clinical and preclinical development targeting human diseases. However, the molecular mechanism that controls the activation of RIPK1 kinase activity remains unclear. Here we show that the intermediate domain of RIPK1 is phosphorylated transiently by TAK1 upon TNFα stimulation in wild-type (WT) cells in vitro and in vivo. While Ser321 (S321) phosphorylation of RIPK1 by TAK1 has no effect on the NF-κB activation, the loss of S321 phosphorylation promotes the binding of RIPK1 to FADD and RDA. On the other hand, the sustained TAK1-mediated phosphorylation of RIPK1 in multiple sites of the intermediate domain including S321 promotes its interaction with RIPK3 to mediate necroptosis. Our results elucidate the molecular mechanism of interaction between TAK1 and RIPK1, two critical mediators in the TNFα signaling pathway, distinct from their roles in the activation of the NF-κB pathway, and the mechanism by which the levels of RIPK1 phosphorylation control the cellular choices for alternative cell death mechanisms. RESULTS Transient RIPK1 S321 phosphorylation upon TNFα stimulation S321 of RIPK1 was found to be phosphorylated in the kidney, lung and spleen tissues of mice under normal conditions in a global phosphoproteomic study and when expressed in 293T cells11, 12. S321 site is evolutionarily conserved in RIPK1 proteins from species including mouse, human, rat and cattle (Fig. 1a). S321 is located in a conserved sequence RMFSLQHDCV in murine RIPK1, or RMQSLQLDCV in human RIPK1. The +1 residue of this peptide is a ‘Leu’, which is also found in +1 residue of S177 in IKKβ known to be phosphorylated by TAK113.Fig. 1TNFα induces RIPK1 phosphorylation at S321. a Alignment of amino acid sequences in the relevant part of RIPK1 intermediate domain from indicated mammalian species. S321, S332, S334 and S336 as marked by arrowheads are highly evolutionarily conserved. b S321 of RIPK1 is transiently phosphorylated after TNFα treatment. MEF cells were treated with TNFα (10 ng/ml) and the samples were collected at indicted time-points. The cell lysates were analyzed by western blot. c Anti-p-S321-RIPK1 antibody specifically recognizes RIPK1 S321 phosphorylation. L929 cells were treated with TNFα (20 ng/ml) for 5 min. The cell lysates were subjected to immunoprecipitation by either RIPK1 antibody or IgG. Both lysates and IP samples were examined by western blot using anti-p-S321-RIPK1 and RIPK1 total antibodies. d, e TNFα induces RIPK1 S321 phosphorylation in murine primary BMDM and microglia cells. BMDM d and primary microglia e were pre-incubated with DMSO or TAK1 inhibitor, 5Z-7 (0.5 µM) for 30 min and treated with TNFα (10 ng/ml). Samples were collected at indicated time-points. *, nonspecific bands To confirm and characterize the significance of S321 phosphorylation, we developed a phospho-specific antibody against p-S321 of mouse RIPK1 (anti-p-S321-RIPK1). We probed western blots of cell lysates from mouse embryonic fibroblast (MEF) cells stimulated with TNFα for different periods of time. After stimulation of TNFα, the RIPK1 band showed a specific up-shift within 5 min TNFα stimulation and the shift reduced after 30–60 min treatment. This shifted band was recognized by anti-p-S321-RIPK1 (Fig. 1b). The phosphorylation of IKKβ, known to be mediated by TAK113, was also detected during the same time frame. Induction of RIPK1 S321 phosphorylation was also found in RGC-5 cells stimulated by TNFα (Supplementary Fig. 1a). To confirm that the band recognized by anti-p-S321-RIPK1 is RIPK1, we immunoprecipitated RIPK1 from cells stimulated by TNFα and probed the immunocomplexes with anti-p-S321-RIPK1. As shown in Fig. 1c, anti-p-S321-RIPK1 specifically recognized immunoprecipitated RIPK1 from TNFα-stimulated cells but not from control cells. In addition to MEF and RGC-5 cells, we verified TNFα induced RIPK1 phosphorylation in primary cells. As that observed in MEFs and RGC-5 cells, in bone marrow-derived macrophages (BMDM) and mouse

Read the complete text